Journal Logo   Journal of Natural Remedies

Metformin - A Panacea Pharmaceutical Agent through convergence revolution initiative


Affiliations

  • Sri Venkateswara College of Engineering, Department of Biotechnology, Pennalu,Kancheepuram District, Sriperambudur, Tamil Nadu, 60211, India
  • Karpaga Vinayaga Institute of Medical Sciences and research center, Department of Medicine, Chinna Kolambakkam, Palayanoor P.O, Kanchipuram Dist, Madurantagam, Tamil Nadu, 603308, India
  • University Malaysia Pahang,Gambang Campus, Faculty of Chemical and Natural Resources Engineering, Gambang, 26300, Malaysia
  • Palms Connect Sdn Bhd, Shah Alam, Selangor Darul Ehsan, 40460, Malaysia

Abstract

Metformin has been known to the mankind for centuries. Metformin is the first line of drug of choice for the treatment of type 2 diabetes. Initial pharmaceutical therapy was for treating the frequent urinal problem which is a primary manifestation of diabetes. At the time of writing, metformin as an intervention is looked into for cardiovascular risks, polycystic ovary syndrome and breast cancer. Annual demand for Metformin is 23,000 Metric tons per annum. Nano Drug Delivery Systems (NDDS) has embarked into Metformin controlled and targeted delivery for breast cancer, pancreatic cancer and non-small cell lung cancer. Clinical estimation of the biological fluids by the FDA approved diagnostic laboratories use LC-MS/MS where blood samples estimate Metformin as an intact molecule easing the pressure of clinical trials result. Metformin was manufactured by a less known and low profile Aoron pharmaceutical, France not aware of the block buster drug hence the potential of technology development start-ups can neither be underwritten nor underestimated even when there is a very high rate (~90%) of failed biotech/biomed start-up ventures. The bloom of the French lilac (metformin) to blossom and flower for the cure of breast cancer by convergence revolution initiative with the integration of academia, hospital, technology business incubator, multinational corporation with the deliverance of a start-up company

Keywords

Antineoplastic Drug, Breast Cancer, Clinical Trials, Metformin, Start-Up Company

Subject Discipline

Pharmaceutical, Breast cancer, Start-up

Full Text:

References

Watanabe CK. Studies in the metabolic changes induced by administration of guanidine bases. J Biol Chem. 1918; 33:253–65.

Werner EA, Bell J. The preparation of guanidine by the interaction of Dicyanodiamide and ammonium thiocyanate. J Chem Soc Trans. 1920; 117:1133. https:// doi.org/10.1039/CT9201701133

Werner EA, Bell J. The Preparation of Methylguanidine, and of ββ-Dimethylguanidine by the Interaction of Dicyanodiamide and Methylammonium and Dimethylammonium Chlorides Respectively. J Chem Soc Trans. 1922; 121:1790. https://doi.org/10.1039/ CT9222101790

Sterne J. Du nouveau dans les antidiabetiques. La NN Dimethylamine Guanyl guanide (NNDG). Maroc Med. 1957; 36:1295–6.

Available from: https://www.accessdata.fda.gov/drugsatfda_ docs/nda/98/020357s010.cfm

DeFronzo RA, Goodman AM. The multicenter metformin study group efficacy of metformin in patients with noninsulindependent diabetes mellitus New England. Journal Medicine. 1995; 333:541–9. https://doi.org/10.1056/ NEJM199508313330902 PMid:7623902

Lennard MS, Casey C, Tucker GT, Woods HF. Determination of metformin in biological samples. Br J clin Pharmac. 1978; 6:183–5. https://doi.org/10.1111/j.1365-2125.1978. tb00852.x

Gabr RQ, Padwal RS, Brocks DR. Determination of metformin in human plasma and urine by highperformance liquid chromatography using small sample volume and conventional octadecyl silane column. J Pharm Pharmaceut Sci. 2010; 13(4):486–494. https://doi.org/10.18433/J32C71

Frid A, Sterner GN, Londahl M, Wiklander C, Cato A, Vinge E, Andersson A. Novel assay of metformin levels in patients with type 2 diabetes and varying levels of renal function. Diabetes Care. 2010; 33(6):1291–2.https://doi.org/10.2337/dc09-1284 PMid:20215446 PMCid:PMC2875440

Kim HK, Park YS. Plasma concentration of metformin and dexamethasone after administration through osseogate. Drug Delivery. 2017; 24(1):437–42. https://doi.org/10.10 80/10717544.2016.1261380 PMid:28165808

Santoro AB, Stage TB, Struchiner CJ, Christensen MM, Brosen K, Suarez-Kurtz G. Limited sampling strategy for determining metformin area under the plasma concentration-time curve. Br J Clin Pharmacol. 2016 82(4):1002–10. https://doi.org/10.1111/bcp.13049 PMid:27324407 PMCid:PMC5137825

Kumar PP, Murthy TE, Rao MVB. Development, validation of liquid chromatography-tandem mass spectrometry method for simultaneous determination of rosuvastatin and metformin in human plasma and its application to a pharmacokinetic study. J Adv Pharm Technol Res. 2015; 6(3):118–24. https://doi.org/10.4103/2231-4040.157982 PMid:26317076 PMCid:PMC4542398

Aburuz S, Millership J, Mcelnay J, Chromatogr B. Determination of metformin in plasma using a new ion pair solid phase extraction technique and ion pair liquid chromatography. Biomed Life Sci. 2003; 798:203–9.https://doi.org/10.1016/j.jchromb.2003.09.043

Cheng C, Chou C. Determination of metformin in human plasma by high-performance liquidchromatography with spectrophotometric detection. J Chromatogr B Biomed Sci Appl. 2001; 762(1):51–8. https://doi.org/10.1016/ S0378-4347(01)00342-5

DeCensi A, Puntoni M, Goodwin P, Cazzaniga M, Gennari A, Bonanni B, Gandini S. Metformin and Cancer risk in diabetic patients: A systematic review and metaanalysis. Cancer Prev Res. 2010; 3:1451–61. https://doi.org/10.1158/1940-6207.CAPR-10-0157 PMid:20947488

Levri KM, Slaymaker E, Last A, Yeh J, Ference J, D’Amico F, Wilson SA. Metformin as treatment for overweight and obese adults: A systematic review. Annals of Family Medicine. 2005; 3(5):457–61. https://doi.org/10.1370/ afm.343 PMid:16189063 PMCid:PMC1466911

van der Aa MP, Hoving V, van de Garde EMW, Boer A, Knibbe CAJ, van der Vorst MMJ. The effect of eighteenmonth metformin treatment in obese adolescents:comparison of results obtained in daily practice with results from a clinical trial. Journal of Obesity. 2016. Article ID 7852648. https://doi.org/10.1155/2016/7852648 PMid:28101379 PMCid:PMC5214571

Pastor-Villaescusa B, Caballero-Villarraso J, Ca-ete MD, Hoyos R, et al. Evaluation of differential effects of metformin treatment in obese children according to pubertal stage and genetic variations: study protocol for a randomized controlled trial Trials. 2016; 17:323. https:// doi.org/10.1186/s13063-016-1403-4 PMid:27432166 PMCid:PMC4950074

Penzias A, Bendikson K, Butts S, et al. Role of metformin for ovulation induction in infertile patients with Polycystic Ovary Syndrome (PCOS): A guideline. Fertil Steril. 2017; S0015-0282(17):30485–5.

Pedersen AJT, Stage TB Glintborg D, Andersen M, Christensen MMH. The pharmacogenetics of metformin in women with PCOS: A randomized trial. Basic Clin Pharmacol Toxicol. 2017. https://doi.org/10.1111/bcpt.12874

O’Brien MJ, Perez A, Scanlan AB, Alos VA, et al. PREVENTDM comparative effectiveness trial of lifestyle intervention and metformin. Am J Prev Med. 2017; 52(6):788–97. https:// doi.org/10.1016/j.amepre.2017.01.008 PMid:28237635

O’Brien MJ, Whitaker RC, Yu D, Ackermann RT. The comparative efficacy of lifestyle intervention and metformin by educational attainment in the Diabetes Prevention Program. Prev Med. 2015; 77:125–30. https:// doi.org/10.1016/j.ypmed.2015.05.017 PMid:26024851 PMCid:PMC4490008

Florez H, Pan Q, Ackermann RT, Marrero DG, et al. Diabetes prevention program research group. Impact of lifestyle intervention and metformin on health-related quality of life: The diabetes prevention program randomized trial. J Gen Intern Med. 2012; 27(12):1594–601. https:// doi.org/10.1007/s11606-012-2122-5 PMid:22692637 PMCid:PMC3509296

The diabetes prevention program research group. Impact of intensive lifestyle and metformin therapy on cardiovascular disease risk factors in the diabetes prevention program. Diabetes Care. 2005; 28(4):888–94.https://doi.org/10.2337/diacare.28.4.888 PMid:15793191 PMCid:PMC1307521

Zakikhani M, Dowling R, Fantus GI, Sonenberg N, Pollak M. Metformin is an AMP Kinase- Dependent growth inhibitor for breast cancer cells. Cancer Res. 2006; 66(21):10269–73. https://doi.org/10.1158/0008-5472.CAN-06-1500 PMid:17062558

Dowling R, Zakikhani M, Fantus G, Pollak M, Sonenberg N. Metformin inhibits mammalian target of rapamycin– dependent translation initiation in breast cancer cells.Available from: http://www.mcgill.ca/pollak-lab/files/ pollak-lab/metformin_inhibits_mammalian_target_of_ rapamycin-dependent_translation_initiation_in_breast_ cancer_cells.pdf

Jiralerspong S, Palla SL, Giordano SH, et al. Metformin and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breast cancer. Journal of Clinical Oncology. 2009; 27(20):3297–302. https://doi.org/10.1200/JCO.2009.19.6410 PMid:19487376 PMCid:PMC2736070

Goodwin PJ, Stambolic V, Lemieux J, Chen BE, et al. Evaluation of metformin in early breast cancer: A modification of the traditional paradigm for clinical testing of anti-cancer agents. Breast Cancer Research and Treatment. 2011; (126):215–20. https://doi.org/10.1007/ s10549-010-1224-1 PMid:20976543

NCT01101438 A Phase III randomized trial of metformin vs placebo in early stage breast cancer: 2010-2017. Available from: https://clinicaltrials.gov/ct2/show/NCT01101438

Lohmann AE, Liebman MF, Brien W, Parulekar WR, et al. Effects of metformin versus placebo on vitamin B12 metabolism in non-diabetic breast cancerpatients in CCTG MA.32. Breast Cancer Res Treat. 2017; 164(2):371–8. https://doi.org/10.1007/s10549-017-4265-x PMid:28447237

Campagnoli C, Pasanisi P, Abba C, Ambroggio S, et al. Effect of different doses of metformin on serum testosterone and insulin in non-diabetic women with breast cancer: a randomized study. Clin Breast Cancer. 2012; 12(3):175–82. https://doi.org/10.1016/j.clbc.2012.03.004 PMid:22607767

Shaw RJ, Kosmatka M, Bardeesy N, et al. The tumor suppressor LKB1 kinase directly activates AMP-activated kinase and regulates apoptosis in response to energy stress. Proc Natl Acad Sci USA. 2004; 101:3329–35. https://doi.org/10.1073/pnas.0308061100 PMid:14985505 PMCid:PMC373461

Katiyar S, Liu E, Knutzen CA, Lang ES, Christian R Lombardo CR, et al. REDD1, an inhibitor of mTOR signalling REDD1, is regulated by the CUL4A–DDB1 ubiquitin ligase. EMBO Reports. 2009; 10(8):866–72.https://doi.org/10.1038/embor.2009.93 PMid:19557001 PMCid:PMC2726664

Aryappalli P, Al-Qubaisi SS, Attoub S, George JA, Arafat K, Ramadi KB, Mohamed YA, Al-Dhaheri MM, Al-Sbiei A, Fernandez-Cabezudo MJ, Al-Ramadi BK. The IL-6/ STAT3 signaling pathway is an early target of manuka honey-induced suppression of human breast cancer cells. Frontiers in Oncology. 2017; 14(7):167. https:// doi.org/10.3389/fonc.2017.00167 PMid:28856117 PMCid:PMC5557744

Oliveras-Ferraros C, Cufí S, Vazquez-Martin A, TorresGarcia VZ, Del Barco S, Martin-Castillo B, Menendez JA. Micro(mi)RNA expression profile of breast cancer epithelial cells treated with the anti-diabetic drug metformin: Induction of the tumor suppressor miRNA let-7a and suppression of the TGFβ-induced oncomiR miRNA-181a. Cell Cycle. 2011 Apr 1; 10(7):1144–51.https://doi.org/10.4161/cc.10.7.15210 PMid:21368581

Algire C, Amrein L, Bazile M, et al. Diet and tumor LKB1 expression interact to determine sensitivity to anti-neoplastic effects of metformin in vivo. Oncogene.2011; 30:1174–82. https://doi.org/10.1038/onc.2010.483 PMid:21102522

Chiang GG, Abraham RT. Targeting the mTOR signaling network in cancer. Trends Mol Med 2007; 13:433-42. https:// doi.org/10.1016/j.molmed.2007.08.001 PMid:17905659

LeRoith D, Roberts CT Jr. Insulin-like growth factors and cancer. Ann Intern Med. 1995; 122:54–9. https:// doi.org/10.7326/0003-4819-122-1-199501010-00009 PMid:7619109

Liu H, Radisky DC, Nelson CM, Zhang H, Fata JE, Roth RA, Bissell MJ. Mechanism of Akt1 inhibition of breast cancer cell invasion reveals a protumorigenic role for TSC2. Proc Natl Acad Sci U S A. 2006; 103(11):4134–9.https://doi.org/10.1073/pnas.0511342103 PMid:16537497 PMCid:PMC1390746

Widen ElM, Eriksson JG, Groop LC. Metformin normalizes nonoxidative glucose metabolism in insulinresistant normoglycemic first-degree relatives of patients with NIDDM. Diabetes. 1992 Mar; 41:354–8. https://doi.org/10.2337/diab.41.3.354 PMid:1551495

Prager R, Schernthaner G, Graf H. Effect of metformin on peripheral insulin sensitivity in non insulin dependent diabetes mellitus. Diabete Metab. 1986 Dec; 12(6):346–50.PMid:3817257

Drzewoski J, Drozdowska A, Sliwińska A. Do we have enough data to confirm the link between antidiabetic drug use and cancer development? Pol Arch Med Wewn. 2011; 121:81–7. PMid:21430609

Shariatinia Z, Zahraee Z. Controlled release of metformin from chitosan-based nanocomposite films containing mesoporous MCM-41 nanoparticles as novel drug delivery systems. J Colloid Interface Sci. 2017; 501:60–76.https://doi.org/10.1016/j.jcis.2017.04.036 PMid:28433886

Xiong Y, Zhao Y, Miao L, Lin M, Huang L. Co-delivery of polymeric metformin and cisplatin by self-assembled core-membrane nanoparticles to treat non-small cell lung cancer. J Control Release. 2016; 244(Pt A):63–73.

Snima KS, Jayakumar R, Unnikrishnan AG, Nair SV, Lakshmanan VK. O-Carboxymethyl chitosan nanoparticles for metformin delivery to pancreatic cancer cells. Carbohydrate Polymers. 2012; 89:1003–7. https:// doi.org/10.1016/j.carbpol.2012.04.050 PMid:24750892

Kumar CS, Raja MD, Sundar DS, Antoniraj MG, Ruckmani K. Hyaluronic acid co-functionalized gold nanoparticle complex for the targeted delivery of metformin in the treatment of liver cancer (HepG2 cells). Carbohydrate Polymers. 2015; 128:63–74. https://doi.org/10.1016/j.carbpol.2015.04.010 PMid:26005140

Hu J, Prabhakaran M, Tian L, Ding X, Ramakrishna S. Drugloaded emulsion electrospun nanofibers: Characterization, drug release and in vitro biocompatibility. RSC Adv. 2015; 5:100256. https://doi.org/10.1039/C5RA18535A

Nurani M, Akbari V, Taheri A. Preparation and characterization of metformin surface modifiedcellulose nanofiber gel and evaluation of its anti-metastatic potentials. Carbohydrate Polymers. 2017; 165:322– 33. https://doi.org/10.1016/j.carbpol.2017.02.067 PMid:28363556

Evans JM, Donnelly LA, Emslie-Smith AM, Alessi DR, Morris AD. Metformin and reduced risk of cancer in diabetic patients. BMJ. 2005 Jun 4; 330(7503):1304– 5. https://doi.org/10.1136/bmj.38415.708634.F7 PMid:15849206 PMCid:PMC558205

Pollak MN. Investigating metformin for cancer prevention and treatment: The end of the beginning. Cancer Discov.2012; 2(9):778–90. https://doi.org/10.1158/2159-8290.CD-12-0263 PMid:22926251

Clinical and biologic effects of metformin in early stage breast cancer 2008-2011. Available from: https:// clinicaltrials.gov/ct2/show/NCT00897884

Effect of metformin on breast cancer metabolism 20102014. Available from: https://clinicaltrials.gov/ct2/show/ NCT01266486

Study of erlotinib and metformin in triple negative breast cancer 2012-2017. Available from: https://clinicaltrials.gov/ct2/show/NCT01650506

Efficacy and safety of adjuvant metformin for operable breast cancer patients 2009-2015. Available from: https:// clinicaltrials.gov/ct2/show/NCT00909506

Myocet + Cyclophosphamide + Metformin Vs Myocet + Cyclophosphamide in 1st line treatment of HER2 Neg. Metastatic Breast Cancer Patients (MYME). 20132015. Available from: https://clinicaltrials.gov/ct2/show/ NCT01885013

Metformin and temsirolimus in treating patients with metastatic or unresectable solid tumor or lymphoma 2008-2013. Available from: https://clinicaltrials.gov/ct2/ show/NCT00659568

A trial of standard chemotherapy with metformin (vs placebo) in women with metastatic breast cancer 20112017. Available from: https://clinicaltrials.gov/ct2/show/ NCT01310231

Metformin pre-surgical pilot study 2009-2017. Available from: https://clinicaltrials.gov/ct2/show/NCT00930579

Khargonekar P, Sinskey A, Miller C, Ranganathan B.Convergence revolution- Piloting the third scientific revolution through start-ups for breast cancer cure. Cancer Sci Res Open Access. 2017; 4(1):1–6. DOI: http://dx.doi.org/10.15226/csroa.2017.00130 https://doi.org/10.15226/ csroa.2017.00130

Ramakrishnan R, Gimbun J, Samsuri F, Narayanamurthy V, Gajendran N, Lakshmi YS, Stranska D, Ranganathan B.Needleless electrospinning technology- an entrepreneurial perspective. Indian J Sci Technol. 2016; 9:1–11. https:// doi.org/10.17485/ijst/2016/v9i15/91538

Ranganathan B, Miller C, Sinskey A. Biocompatible synthetic and semi-synthetic polymers- A patent preliminary analysis. Pharm Nanotechnol. 2017 Oct 23. DOI: 10.2174/2211738505666171023152549. [Epub ahead of print].


Refbacks

  • There are currently no refbacks.